A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
for Metastatic Uveal Melanoma
Drug: Nivolumab
Sites in Chicago +28 more locations
Sponsor: Replimune, Inc.
Sex: All·Age: All ages
Code: NCT06581406·Phase 2, Phase 3·Recruiting·Listed Sep 2024